Tvardi Therapeutics is developing oral small molecule therapies that target STAT3 to treat fibrosis-driven diseases, including liver cancer and idiopathic pulmonary fibrosis (IPF). The company addresses the significant unmet medical need for effective treatments in these conditions, which currently lack adequate therapeutic options.
Funding
$111.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SPFounders
Product
Problem
Fibrosis-driven diseases like liver cancer and idiopathic pulmonary fibrosis (IPF) present significant medical challenges due to limited effective treatment options. Current therapies often fail to adequately address the underlying mechanisms of fibrosis, leading to disease progression and poor patient outcomes.
Solution
Tvardi Therapeutics is developing a new class of oral small molecule therapies designed to selectively inhibit STAT3, a key signaling protein involved in the fibrotic process. By targeting STAT3, Tvardi's therapies aim to disrupt the progression of fibrosis in diseases such as liver cancer and IPF. These therapies are designed to be orally bioavailable, offering a convenient route of administration for patients. The company's lead compounds are currently in clinical trials, evaluating their safety and efficacy in patients with advanced liver cancer and IPF. Tvardi's approach seeks to address the root cause of fibrosis, potentially leading to disease modification and improved patient survival.
Target Audience
The primary target audience includes patients diagnosed with fibrosis-driven diseases such as liver cancer and idiopathic pulmonary fibrosis (IPF), as well as the physicians who treat them, including oncologists and pulmonologists.
Features
- Orally bioavailable small molecule inhibitors of STAT3
- Selective targeting of STAT3 signaling to disrupt fibrotic pathways
- Clinical-stage development programs in liver cancer and idiopathic pulmonary fibrosis (IPF)
- Designed for convenient oral administration
- Aims to modify disease progression by targeting the underlying cause of fibrosis